AR083561A1 - Preparacion de una construccion antigenica - Google Patents
Preparacion de una construccion antigenicaInfo
- Publication number
- AR083561A1 AR083561A1 ARP110103959A ARP110103959A AR083561A1 AR 083561 A1 AR083561 A1 AR 083561A1 AR P110103959 A ARP110103959 A AR P110103959A AR P110103959 A ARP110103959 A AR P110103959A AR 083561 A1 AR083561 A1 AR 083561A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigenic
- preparation
- peptide
- construction
- antigenic construction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Un método para preparar construcciones a base de liposomas que comprende un péptido, particularmente un péptido antigénico, de interés modificado a través de restos hidrófobos reconstituidos en liposomas y las construcciones antigénicas obtenidas con dicho método. Uso de dichas construcciones para el uso terapéutico y de diagnóstico en el tratamiento de enfermedades y trastornos, que son causados por, o asociados con, proteopatía tal como la enfermedad de Alzheimer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10188832 | 2010-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083561A1 true AR083561A1 (es) | 2013-03-06 |
Family
ID=44872345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110103959A AR083561A1 (es) | 2010-10-26 | 2011-10-26 | Preparacion de una construccion antigenica |
Country Status (10)
Country | Link |
---|---|
US (1) | US9687447B2 (es) |
EP (1) | EP2632434A1 (es) |
JP (1) | JP6027011B2 (es) |
KR (1) | KR101854943B1 (es) |
CN (1) | CN103189050B (es) |
AR (1) | AR083561A1 (es) |
AU (1) | AU2011322553B2 (es) |
CA (1) | CA2813833C (es) |
TW (1) | TW201223561A (es) |
WO (1) | WO2012055933A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140314837A1 (en) * | 2011-09-23 | 2014-10-23 | Ac Immune S. A. | Vaccine Therapy |
JP6697384B2 (ja) | 2013-07-25 | 2020-05-20 | イグジキュア, インコーポレーテッドExicure, Inc. | 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物 |
CN103601796B (zh) * | 2013-11-11 | 2016-09-21 | 杭州璞题生物科技有限公司 | 亨廷顿蛋白的棕榈化修饰方法 |
CN112107693B (zh) | 2013-12-03 | 2023-05-26 | 西北大学 | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 |
JP6019254B2 (ja) | 2014-04-23 | 2016-11-02 | 株式会社ニチレイバイオサイエンス | 標的マーカー検出用組合せ物 |
ES2725948T3 (es) | 2014-06-04 | 2019-09-30 | Exicure Inc | Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas |
JP6741673B2 (ja) | 2014-10-06 | 2020-08-19 | イグジキュア, インコーポレーテッドExicure, Inc. | 抗tnf化合物 |
US20200297867A1 (en) * | 2016-02-01 | 2020-09-24 | Exicure, Inc. | Surface functionalization of liposomes and liposomal spherical nucleic acids (snas) |
CA3023451A1 (en) | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
US11690920B2 (en) | 2017-07-13 | 2023-07-04 | Northwestern University | General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles |
KR20200077543A (ko) * | 2017-10-25 | 2020-06-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 인산화 타우 펩티드의 조성물 및 이의 용도 |
CA3086879A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
PE20201344A1 (es) | 2018-04-10 | 2020-11-25 | Ac Immune Sa | Vacunas terapeuticas anti-abeta |
CN112165956A (zh) * | 2018-04-10 | 2021-01-01 | Ac免疫有限公司 | 抗Aβ治疗性疫苗 |
US20210378961A1 (en) * | 2018-07-24 | 2021-12-09 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof |
EP3877399A4 (en) | 2018-11-06 | 2022-10-19 | Alsatech, Inc. | CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES |
WO2020163730A2 (en) | 2019-02-08 | 2020-08-13 | Ac Immune S.A. | Method of safe administration of phosphorylated tau peptide vaccine |
CN114206444A (zh) | 2019-04-18 | 2022-03-18 | Ac免疫有限公司 | 用于治疗和诊断的新分子 |
EP3965817A4 (en) | 2019-04-24 | 2023-11-22 | Janssen Pharmaceuticals, Inc. | HETEROLOGUE ADMINISTRATION OF TAU VACCINES |
BR112021023209A2 (pt) | 2019-05-21 | 2022-01-18 | Ac Immune Sa | Terapia com vacina anti-abeta |
MX2021014274A (es) | 2019-05-23 | 2022-01-06 | Ac Immune Sa | Moleculas de union anti-tdp-43 y usos de las mismas. |
US20230034474A1 (en) | 2019-09-10 | 2023-02-02 | Ac Immune Sa | Novel Molecules for Diagnosis |
JP2023504699A (ja) | 2019-12-04 | 2023-02-06 | エイシー イミューン ソシエテ アノニム | 治療および診断のための新規な分子 |
US11913964B2 (en) * | 2020-02-27 | 2024-02-27 | Adeptrix Corp. | Multiplexed bead-based analytical assays |
US20220287970A1 (en) * | 2020-06-30 | 2022-09-15 | Eyegene Inc | Composition for inhibiting saponin-induced hemolysis, containing cationic liposome |
CN116615452A (zh) | 2020-08-14 | 2023-08-18 | Ac免疫有限公司 | 人源化抗tdp-43结合分子及其用途 |
WO2022079297A1 (en) | 2020-10-16 | 2022-04-21 | Ac Immune Sa | Antibodies binding to alpha-synuclein for therapy and diagnosis |
TW202342519A (zh) | 2022-02-16 | 2023-11-01 | 瑞士商Ac 免疫有限公司 | 人源化抗tdp-43結合分子及其用途 |
WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4565696A (en) | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
DE3683688D1 (de) * | 1985-04-19 | 1992-03-12 | Wistar Inst | Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5620689A (en) | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
US6004555A (en) | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US6036955A (en) | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US5877289A (en) | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
ATE239506T1 (de) | 1992-03-05 | 2003-05-15 | Univ Texas | Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren |
IT1257893B (it) | 1992-06-17 | 1996-02-16 | Ist Superiore Sanita | Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana. |
WO1994002178A1 (en) | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
EP0669941A1 (en) * | 1992-11-02 | 1995-09-06 | NICOLAU, Yves Claude | Method of reducing multidrug resistance in cells and tissues |
US20040248799A1 (en) | 1993-05-27 | 2004-12-09 | Holaday John W. | Compositions and methods for treating cancer and hyperproliferative disorders |
JP3759759B2 (ja) | 1994-03-04 | 2006-03-29 | 日本油脂株式会社 | リポソームおよび薬物運搬体 |
CA2137297C (en) | 1993-12-06 | 2000-04-18 | Tsuyoshi Miyazaki | Reactive vesicle and functional substance-fixed vesicle |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
BR9509421A (pt) | 1994-10-21 | 1997-09-30 | Innogenetics Nv | Novas sequências de genotipos de vírus de hepatite C e uso como agentes profiláticos terapêuticos e diagnósticos |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
CN1196785C (zh) | 1997-04-16 | 2005-04-13 | 惠氏 | β-淀粉样肽结合蛋白及其编码聚核苷酸 |
JP4385152B2 (ja) | 1997-09-17 | 2009-12-16 | 三菱化学株式会社 | 2価反応性水溶性高分子誘導体及びそれを含有する複合体 |
KR19990029749A (ko) | 1997-09-17 | 1999-04-26 | 미우라 아끼라 | 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체 |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
AU2600499A (en) | 1998-02-13 | 1999-08-30 | Arch Development Corporation | Methods and compositions comprising the use of blocked b-amyloid peptide |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
US6025160A (en) | 1998-07-22 | 2000-02-15 | Smithkline Beecham Corporation | Polynucleotide and polypeptide sequences encoding rat mdr1b2 and screening methods thereof |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
ES2344189T3 (es) | 1999-09-03 | 2010-08-20 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer. |
US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
US7442776B2 (en) | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
AU781729B2 (en) | 1999-12-22 | 2005-06-09 | Nektar Therapeutics | Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) |
US6521635B1 (en) | 2000-01-20 | 2003-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of MXR transport by acridine derivatives |
US20030086938A1 (en) | 2000-02-21 | 2003-05-08 | Jensen Martin Roland | Novel methods for down-regulation of amyloid |
JP2002047298A (ja) | 2000-07-10 | 2002-02-12 | Academia Sinica | 新規抗がん剤伝達系 |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
AU2001286405B2 (en) | 2000-07-31 | 2007-05-10 | Yale University | Innate immune system-directed vaccines |
US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
EP2067863A3 (en) | 2000-09-06 | 2013-11-06 | Aventis Pharma S.A. | Methods and compositions for diseases associated with amyloidosis |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
ES2228697T3 (es) | 2001-06-12 | 2005-04-16 | Wiltfang, Jens | Anticuerpo monoclonal, mab 1e8, que es especifico para los dos primeros aminoacidos de peptidos beta-amiloides y su utilizacion en la deteccion de peptidos beta-amiloides y/o sapp alfa. |
DK1397380T3 (da) | 2001-06-20 | 2007-05-07 | Univ Ramot | Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf |
DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
CA2504349A1 (en) | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid |
US20030229013A1 (en) | 2001-12-07 | 2003-12-11 | Shih-Kwang Wu | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US20080233181A1 (en) * | 2002-04-12 | 2008-09-25 | Nagy Jon O | Nanoparticle adjuvants for sub-unit vaccines |
EP1523499A2 (en) | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
CN100386068C (zh) | 2002-12-03 | 2008-05-07 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
JP2006525226A (ja) | 2002-12-24 | 2006-11-09 | ニューロケム (インターナショナル) リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
RU2390350C2 (ru) | 2003-02-01 | 2010-05-27 | Ньюралаб Лимитед | Активная иммунизация для создания антител к растворимому а-бета |
US8663650B2 (en) * | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
US20040242845A1 (en) | 2003-02-21 | 2004-12-02 | Nicolau Yves Claude | Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them |
NZ543934A (en) | 2003-05-12 | 2008-06-30 | Affymax Inc | Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds |
FR2857875A1 (fr) | 2003-07-25 | 2005-01-28 | Univ Reims Champagne Ardenne | Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers |
WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
SI2465533T1 (sl) | 2004-02-20 | 2015-07-31 | Ac Immune S.A. | Postopki in sestavki, ki obsegajo supramolekulske konstrukte |
JP2008524237A (ja) | 2004-12-17 | 2008-07-10 | ダイナバックス テクノロジーズ コーポレイション | 免疫寛容の誘導又は促進のための方法及び組成物 |
BRPI0619747B8 (pt) | 2005-12-12 | 2021-05-25 | Ac Immune Sa | método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide |
EP2808032B1 (en) | 2005-12-12 | 2018-08-01 | AC Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
US8394758B2 (en) | 2008-10-29 | 2013-03-12 | Academia Sinica | Tumor-targeting peptides and uses thereof |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція |
-
2011
- 2011-10-26 CN CN201180051932.3A patent/CN103189050B/zh active Active
- 2011-10-26 EP EP11775949.8A patent/EP2632434A1/en active Pending
- 2011-10-26 KR KR1020137013183A patent/KR101854943B1/ko active IP Right Grant
- 2011-10-26 TW TW100139025A patent/TW201223561A/zh unknown
- 2011-10-26 US US13/881,502 patent/US9687447B2/en active Active
- 2011-10-26 WO PCT/EP2011/068797 patent/WO2012055933A1/en active Application Filing
- 2011-10-26 AU AU2011322553A patent/AU2011322553B2/en active Active
- 2011-10-26 JP JP2013535421A patent/JP6027011B2/ja active Active
- 2011-10-26 AR ARP110103959A patent/AR083561A1/es not_active Application Discontinuation
- 2011-10-26 CA CA2813833A patent/CA2813833C/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6027011B2 (ja) | 2016-11-16 |
CN103189050B (zh) | 2017-09-29 |
AU2011322553B2 (en) | 2015-07-02 |
EP2632434A1 (en) | 2013-09-04 |
KR101854943B1 (ko) | 2018-05-04 |
CA2813833C (en) | 2020-09-22 |
AU2011322553A1 (en) | 2013-04-18 |
CA2813833A1 (en) | 2012-05-03 |
US9687447B2 (en) | 2017-06-27 |
CN103189050A (zh) | 2013-07-03 |
TW201223561A (en) | 2012-06-16 |
US20130224287A1 (en) | 2013-08-29 |
KR20140009206A (ko) | 2014-01-22 |
JP2014503475A (ja) | 2014-02-13 |
WO2012055933A1 (en) | 2012-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR083561A1 (es) | Preparacion de una construccion antigenica | |
CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
BR112014011404A2 (pt) | moléculas de anticorpos com especificidade para o ox40 humano | |
UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
CO6331297A2 (es) | Composiciones adyuvantes novedosas | |
CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
CR20130033A (es) | Formulaciones de rifaximina y usos de las mismas | |
UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
CR20110608A (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
UY33277A (es) | Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso | |
BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
CL2012002175A1 (es) | Composicion farmaceutica oral de liberacion prolongada que comprende un agente activo de fracciones de propargilamina y aminoindano; metodo de preparacion; uso en el tratamiento de enfermedades neurodegenerativas o lesiones en el sistema nervioso tales como parkinson o alzheimer, un accidente cerebrovascular o lesion traumatica cerebral. | |
UY33276A (es) | Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y métodos de uso | |
UA114286C2 (uk) | Спосіб лікування staphylococcus aureus | |
CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
MX2014001393A (es) | 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas. | |
CY1118402T1 (el) | Η χρηση πηγης l3 και/ή l5 ως εμβολιου ή ως διαγνωστικου για παρασιτικη παθηση | |
PH12015502844A1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
EP4321218A3 (en) | Cancer stem cell targeted cancer vaccines | |
WO2016183223A3 (en) | Targeted protein contrast agents, methods of making, and uses thereof | |
AR076892A1 (es) | Conjugados de albumina-peptido amiloide y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |